Nanoparticle shape has emerged as a key regulator of nanoparticle transport across physiological barriers, intracellular uptake and biodistribution. We report a facile approach to synthesize ellipsoidal nanoparticles via self-assembly of poly(glycerol sebacate)-copoly(ethylene glycol) (PGS-co-PEG). The PGS-PEG nanoparticle system is highly tunable, and the semi-axis length of the nanoparticles can be modulated by changing PGS-PEG molar ratio and incorporating therapeutics. As both PGS and PEG are highly biocompatible, the PGS-co-PEG nanoparticles show high hemo-, immuno-and cyto-compatibility. Our data suggest that PGS-co-PEG nanoparticles have the potential for use in a wide range of biomedical applications including regenerative medicine, stem cell engineering, immune modulation and cancer therapeutics.
Introduction
Nanoengineered particles have been extensively investigated for delivery of therapeutics to cells and tissues for regenerative medicine, stem cell engineering, immune modulation, and cancer therapeutics. [1] [2] [3] [4] By modulating the physiochemical characteristics of nanoparticles, therapeutic efficacy, cellular internalization, biodistribution and in vivo retention can be customized. [5] [6] [7] [8] [9] For example, the size of these nanoparticles regulates their own uptake by the healthy (stem cells) or diseased cells (such as tumors or immune cells). [10] [11] [12] [13] [14] Smaller nanoparticles (~25 nm) are preferentially transported through the lymphatics drainage system to draining lymph nodes compared to larger (~100 nm) nanoparticles. 15 Smaller spherical nanoparticles are effective in delivering cargo within the cellular structures as they are readily endocytosed by cells compared to larger size nanoparticles. Whereas, for extracellular delivery and prolonged retention of therapeutics, larger sized nanoparticles have been shown to higher efficacy compared to smaller size nanoparticles. [5] [6] [7] [8] 10 Recently, along with the size, the shape of the nanoparticles has also emerged as a key regulator of intracellular delivery and therapeutic transport efficacy across physiological barriers. [16] [17] [18] [19] In addition, non-spherical nanoparticles have been shown to respond differently to endocytosis, intracellular retention, and in vivo circulation time. For example, elongated nanoparticles show a superior pharmacokinetics profile and reduced non-specific cellular uptake compared to spherical nanoparticles. 18, 20, 21 In addition, non-spherical nanoparticles have shown to respond differently to endocytosis, intracellular retention, and in vivo circulation time. For example, elongated nanoparticles showed a superior pharmacokinetics profile and reduced non-specific cellular uptake compared to spherical nanoparticles. 22 Thus, there is extensive interest in investigating the potential of non-spherical nanoparticles for therapeutic delivery. Non-spherical nanoparticles, such as nanorods and nanodiscs, are effectively taken up by cells compared to their spherical counterpart. [23] [24] [25] [26] [27] The exact mechanism responsible for preferential internalization of non-spherical particles compared to spherical particles is not well understood. However, increasing the surface area of rod-and disc-shaped nanoparticles as compared to spherical nanoparticles is believed to play an important role during cellular internalization. [23] [24] [25] [26] [27] Nanoparticles with large surface-contact area results in stronger adhesion force and thus promote faster cellular uptake, compared to particles with small surfacecontact area. Internalization of nanoparticles is attributed to complex interplay between the surface area in contact with the cell membranes and strain energy required for membrane deformation. [23] [24] [25] [26] [27] The majority of recent studies in this area have focused on non-spherical shapes such as rods and discs 6, 19, 21 ; however, little information exists on the role of ellipsoidal-shaped nanoparticles. Similar to rod-shaped nanoparticles, ellipsoidal nanoparticles also have higher surface-to-volume ratio compared to spherical nanoparticles. 28 Due to absence of any sharp edges in ellipsoidal nanoparticles, surface strain required by cell membrane will be lower compared to rod-shaped nanoparticles. Accordingly, ellipsoidal nanoparticles for therapeutic delivery need further study. However, due to the lack of suitable polymers, it is difficult to fabricate ellipsoidal nanoparticles using conventional techniques such as self-assembly, flash nanoprecipitation and microfluidics-based preparation.
28-31
Here, we report synthesis of self-assembled ellipsoidal nanoparticles from copolymer consisting of poly(glycerol sebacate) (PGS) and poly(ethylene glycol) (PEG 38, 39 It is our expectation, that PEGylating of PGS can improve hydrophilicity, increases stability in serum, and prolong circulation. We synthesized PGS-co-PEG copolymer with different PGS:PEG molar ratio. Nanoparticles from PGS-co-PEG polymers will be synthesized via the nanoprecipitation method.
PEGylation of PGS, results in formation of a core-shell nanoparticles with PGS core and PEG shell. We will investigate the hemo-, immune-and cyto-compatibility of PGS-PEG nanoparticles. Our report introduces a new family of ellipsoidal PGS-PEG nanoparticles for intercellular delivery and can be used to deliver a range of biomolecules for biomedical applications. 
Experimental
Synthesis of copolymer: PGS-co-PEG polymers were synthesized by two-step polycondensation reaction with two different molar ratios of PEG segment (20 and 40) within the copolymer system using previously reported method. 40 The first step involved the polycondensation of sebacic acid (20.22 gm) and poly (ethylene glycol) (20 or 40 gm) in 250mL three neck flask under stirring conditions. PEG was dried in vacuum chamber at 90°C before its use. The reaction was carried out further at 130°C under the flow of argon for 2h
and under vacuum of 50mTorr for another 24h. In the second step a specific amount of glycerol (7.368 gm) was added, mixed thoroughly under the flow of argon and the reaction was carried out at 130°C under reduced pressure of 50mTorr for another 48h. 40 Gel permeation chromatography (GPC, Waters, Milford, MA) was used to determine the molecular weight of copolymers using tetrahydrofuran (THF) as solvent. The overall diol to dicarboxylic acid molar ratio was kept constant. Two molar ratios of PEG to glycerol (20/80, and 40/60) were used to develop PGS-co-PEG polymers with different degrees of PEG segments within the resulting copolymer system. A close control over the condensation reaction resulted in narrow polydispersity index (PDI) for PGS-20PEG (M w~4 998Da, PDI=1.48) and PGS-40PEG (M w~4 037 Da, PDI=1.42).
Synthesis of nanoparticle:
Nanoprecipitation method is extensively used to synthesize polymeric nanoparticles and to entrap hydrophilic drugs or proteins. 41, 42 Here, we have prepared PGS-co-PEG nanoparticles via the nanoprecipitation method (Fig 1a) . Briefly, 5%
(w/v) of the polymer was dissolved in DMSO and was slowly added drop wise to an aqueous phase to obtain self-assembled nanoparticles. The resulting solution was homogenized using a bath sonicator. Finally, the nanoparticles were collected at 17,000 rpm (20 minutes) using
Beckman Optima TM MAX-XP tabletop ultracentrifuge fitted with TLA-55 Rotor and washed Physicochemical characterization of nanoparticles: The mean particle size (hydrodynamic diameter), and electrophoretic mobility of PGS-co-PEG nanoparticles were determined using dynamic light scattering (DLS) (Malvern Instrument, UK) (n=3). The electrophoretic mobility of the co-polymers was also measured using DLS (n=3). The stability of nanoparticles under physiological conditions (in PBS and T=37°C) was monitored for three weeks. The morphological characterization of the nanoparticles was performed using JEOL JEM-2010 transmission electron microscopy (TEM) by loading nanoparticle suspension on lacey carbon grid. The sizes of the nanoparticles were quantified using ImageJ (NIH) by counting >250 particles from TEM images to determine length and width of the nanoparticles. (100 U/100 µg/ml); Life Technologies, USA) and were allowed to adhere for 1 day. After 1 day, cells were treated with PGS-co-PEG at different concentrations (0.15, 0.3, 0.6, 1.25, 2.5, 5, 10 mg/mL). After incubating for 3 h and 24 h, the cells were washed with PBS (2X) and fixed with glutaraldehyde solution (2%) for 10-15 minutes. The fixed cells were stained with rhodamine-labeled phalloidin (R415, Life Technology, USA) and counter stained with 4'6-diamidino-2-phenylindole dilactate (DAPI). The cells were imaged using fluorescence microscope (TE a2000-S, Nikon, USA). Nanoparticles cytotoxicity was determined using the
2H-tetrazolium) according to the manufacturer's protocol.
Hemocompatibility of nanoparticles:
The hemolytic ability of our nanoparticles was investigated using a previously reported method 43 
Immunocompatibility of nanoparticles:
Macrophage activation studies were performed by seeding 20,000 RAW 264.7 murine macrophage cell line (ATCC) in a 24-well plate (n=3).
Following 24 h of incubation, nanoparticles were reconstituted in PBS and introduced to the cells at two different doses: 10 and 100 µg/mL. Analysis on macrophage activation was carried out after 48 h of incubation using flow cytometry with antibodies (eBioscience) targeted against two macrophage activation cell surface markers: CD80 and CD86.
Statistical analysis:
The data was presented as mean ± standard deviation (n=3-5). Statistical analysis was performed using a one-way analysis of variance (ANOVA) with Turkey's post hoc test for pairwise comparison. Statistical significance is designated with via an asterisk *p<0.05. 
Results and discussion

Synthesis and Characterization of Ellipsoidal Nanoparticles
Nanoparticles from PGS-co-PEG polymers were synthesized via the nanoprecipitation method (Fig 1a) . Briefly, copolymer was dissolved in DMSO and added to phosphate buffer saline (PBS) in a drop-wise manner to obtain self-assembled nanoparticles. This technique was based on dissolving the polymer in a water-miscible solvent followed by drop wise addition to an excess volume of aqueous phase with continual stirring. The nanoparticles were formed and precipitated during the solvent evaporation.
We hypothesized that PGS-PEG nanoparticles were formed due to the self-assembly by noncovalent interactions, which results in formation of highly organized supramolecular systems. PGS-co-PEG is an amphiphilic copolymer composed of hydrophobic PGS and hydrophilic PEG blocks with different polarities. PGS-co-PEG is completely dissolved in DMSO, but in aqueous solution they form supramolecular assemblies due to thermodynamic incompatibility between PGS and PEG blocks. It is expected that the interfacial tension between the PGS-co-PEG and the solvent mixture might result in the formation of PGS-PEG nanoparticles. When we prepared nanoparticles using PGS alone, nanoparticles were forming but started aggregating in few minutes and settle down. A plausible reason for this observation could be the hydrophobic nature of PGS. It might be possible that by modulating the molecular weight or type of solvent used, it is possible to obtain stable PGS nanoparticles.
In current study, we modified PGS with PEG to increase the hydrophilicity and to provide stability to the nanoparticles. to the presence of hydroxyl groups on the PGS backbone (Fig 1b) . After nanoparticle formation, the zeta potentials were decreased to -21.3±3.9 mV and -23.7±3.5 mV for PGS-20PEG and PGS-40PEG, respectively. The decrease in zeta potential suggests that PGS formed the core of the nanoparticles and PEG shielded the surface of the nanoparticles to provide aqueous stability. Other studies have shown the formation of core-shell nanoparticles from copolymer systems such as poly(lactic-co-glycolic acid) (PLGA)-co-PEG 44 , poly (d, llactic acid)(PLA)-co-PEG 45 and poly(caprolacton)(PCL)-co-PEG 46 . In addition, nanoparticles containing PEG chains on their surface have ability to provide stealth characteristics 47 and thus can be used for systemic drug administration. 37 
Morphology of Self-assembled Nanoparticles
To determine the morphology of self-assembled nanoparticles, transmission electron microscopy (TEM) and dynamic light scattering (DLS) were used. TEM indicated formation of elongated ellipsoidal nanoparticles from PGS-20PEG and PGS-40PEG (Fig. 1c) .
Quantification of images using IMAGE J (NIH) determined that PGS-20PEG nanoparticles
were ~235±132 nm in length and ~48±28 nm in width and PGS-40PEG nanoparticles were ~195±110 nm in length and ~80±48 nm in width (Fig. 1c) This is due to enhanced interfacial surface between nanoparticles and cell membrane.
From TEM and DLS studies, it is observed that we can modulate the size of elliptical nanoparticles by controlling the molar ratio between PGS and PEG. We hypothesize that the elliptical nanoparticles are formed due to block characteristics of PGS-PEG copolymer and thermodynamic incompatibility between different blocks. By modulating the ratio between PGS and PEG in the copolymer system, we can change the hydrodynamic volume fraction of PGS block with respect to the PEG block. The ratio between PGS and PEG block was also shown to dictate size of major and minor axis in the elliptical nanoparticles.
Modulating Size of Nanoparticle via Therapeutic Loading
The size of nanoparticles has shown to play an important role in cellular internalization, tissue localization and biodistribution. 49, 50 The nanoprecipitation technique can be used to encapsulate a range of hydrophilic drugs and protein within nanoparticle. 41, 42 To evaluate the feasibility of loading a therapeutic protein within the PGS-co-PEG nanoparticles, we selected fluorescein isothiocyanate-labeled bovine serum albumin (FITC-BSA) as a model protein.
FITC-BSA was encapsulated within nanoparticles using the nanoprecipitation method. The encapsulation efficiency of these nanoparticles was 88.5% and 91% for PGS-20PEG and PGS-40PEG, respectively. The TEM and DLS data indicated an increase in the size of nanoparticles with an increase in protein loading (Fig. 2a & 2b) . The addition of 25, 50, and 
Hemo-and immune-compatibility of Ellipsoidal Nanoparticles
The surface characteristics of nanoparticles determine hemo-and immune-compatibility of For systemic administration for targeted and controlled drug delivery, the mechanism of interaction of nanoparticles with blood needs to be investigated. In vivo circulation time 51 We investigated the hemocompatibility of nanoparticles by determining the release of hemoglobin from red blood cells (erythrocytes) and whole blood after exposure to PGS-PEG nanoparticles (Fig. 3a) .
Purified bovine red blood cells (erythrocytes) were obtained by separating plasma proteins from whole blood and were subjected to different concentration of nanoparticles to investigate hemolysis ability of nanoparticles. After 24 h of incubating the nanoparticles with red blood cells and whole blood, the supernatant was used to quantify hemolysis. PGS-20PEG nanoparticles showed no hemolysis at a low concentration (<1 µg/mL). However, at higher PGS-20PEG nanoparticle concentrations (5 µg/mL and 10 µg/mL), 5-10% hemolysis was observed. Interestingly, when the same experiment was performed with PGS-40PEG nanoparticles, we observed less than 2% hemolysis after 3 h of incubation, even for the highest nanoparticle concentration. While no hemolysis was observed in whole blood in both type of nanoparticles. This might be due to presence of serum protein that might prevent any hemolysis in whole blood. Our findings indicate that an increase in PEG concentration increases the hemocompatibility of the nanoparticles. These results are in accordance with the literature supporting the ability of PEGylation to enhance hemocompatibility of nanoparticles.
52,53
Polymeric nanoparticles with long-circulating time are able to improve the clinical efficacy of therapeutic delivery by improving pharmacokinetics, drug localization and delivery efficacy. 54,55 Nanoparticles with stealth capability are able to have long circulating time, as they are able to maintain their structural stability without elicit an immune response. 56, 57 The stealth capability of PGS-co-PEG nanoparticles is expected to improve the immunocompatibility of nanoparticles. We evaluated the immunocompatibility of nanoparticles by monitoring the expression level of two co-stimulatory molecules-CD80 and (Fig. 3b) . In contrast, lipopolysaccharide, a potent immunostimulatory component of bacterial membrane, induced a significant increase in CD80 and CD86 surface expression on macrophages. This highlights the high immunocompatibility of PGS-co-PEG nanoparticles.
In vitro Cytocompatibility of Ellipsoidal Nanoparticles
The in vitro compatibility of PGS-co-PEG nanoparticles was investigated using preosteoblast cells (MC3T3). Cellular viability, proliferation, and morphology were evaluated at different nanoparticle concentrations. The effect of nanoparticles on cellular morphology was monitored by staining the cells for actin cytoskeleton and nucleus after 3 h and 24 h incubation (Fig. 4a) . The untreated cells were flat and adherent to the substrate, with well- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w
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The quantitative cytotoxicity of these ellipsoidal nanoparticles was evaluated by monitoring mitochondrial activity, which affects cell viability and metabolic activity through MTS assay.
The results showed that the metabolic activity of the cells did not change after 3 h or 24 h at lower concentrations by either of the compositions. For example, at low nanoparticle concentration (<1 mg/mL), no significant change in cellular viability was observed. However, at a higher nanoparticle concentration (>1 mg/mL), a sudden decrease in cellular viability was observed. The half maximal inhibitory concentration (IC 50 ) for PGS-co-PEG nanoparticles was determined by fitting the dose response curve to the experimental data. The IC 50 for PGS-20PEG and PGS-40PEG was obtained around 6.3 mg/mL after 24 h exposure.
The IC 50 of PGS-20PEG and PGS-40PEG nanoparticles were similar to other types of nanoparticles such as PLGA and PLGA-co-PEG nanoparticles.
42,44,60,61
Intracellular Delivery via Nanoparticles
To further investigate cellular effects of nanoparticles, the internalization of nanoparticles on the endocytosis pathways of preosteoblast and endothelial cells was determined using flow cytometry. Specifically, three different endocytosis pathways-micropinocytosis, calveolaemediated and clathrin-mediated-were blocked using their respective inhibitor drugs wortmannin, nystatin, and chlorpromazine. [62] [63] [64] Cells were treated with empty nanoparticles, and FITC-BSA loaded PGS-20PEG nanoparticles in presence of different inhibitory drugs and compared with untreated cells. There was no significant difference between empty nanoparticles and untreated cells, this was due to absence of FITC-BSA in nanoparticles. The results showed that wortmannin and chlorpromazine showed significant suppression of cellular uptake of nanoparticles as compared to the control (no drug), indicating that micropinocytosis and clathrin-mediated endocytosis pathways are predominately responsible for nanoparticles uptake (Fig. 5) . The mean fluorescence intensity of cells treated with and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w 17 without nanoparticles indicated a higher uptake of nanoparticles by preosteoblasts compared to endothelial cells.
Conclusions
We introduce a novel yet effective mode of synthesis of a self-assembled ellipsoidal nanoparticle system consisting of an amphiphilic copolymer derived from poly (glycerol sebacate) and poly(ethylene glycol) for therapeutic delivery. The proposed PGS-co-PEG nanoparticle system is highly tunable, and the semi-axis length of the nanoparticle can be modulated by therapeutic loading. PGS-co-PEG nanoparticles showed high cyto-, immuneand hemo-compatibility. Furthermore, the results of this study indicate that ellipsoidal nanoparticles could have a wide range of highly promising applications for proteins and peptide delivery which is claimed to be one of the rapidly developing key components in modern medical breakthrough such as regenerative medicine, stem cell engineering, immune modulation, and cancer therapeutics. The size distribution of PGS-co-PEG nanoparticles was measured using TEM and DLS. TEM images show formation of ellipsoidal nanoparticles from PGS-20PEG and PGS-40PEG. TEM image analysis using ImageJ (NIH) was used to determine the major and minor axis dimension. The histogram represents average of minimum 100 nanoparticles. DLS data show decreased hydrodynamic diameter due to increase in PEG concentration in copolymer.
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